{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:52Z","timestamp":1786991212871,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaad.2020.04.074","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:38:45Z","timestamp":1587555525000},"page":"1425-1433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature"],"prefix":"10.1016","volume":"83","author":[{"given":"Alana","family":"Deutsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Balagula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth N.","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2020.04.074_bib1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2310\/7750.2013.12092","article-title":"Eruptive squamous cell carcinomas after vemurafenib therapy","volume":"17","author":"Mays","year":"2013","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.074_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/annonc\/mds292","article-title":"Cutaneous effects of BRAF inhibitor therapy: a case series","volume":"24","author":"Mattei","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2310\/7750.2013.13120","article-title":"Cutaneous adverse events during vemurafenib therapy","volume":"18","author":"Chandrakumar","year":"2014","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/15569527.2014.949345","article-title":"Virologic and genetic evaluation of vemurafenib-induced skin cancers","volume":"34","author":"Dika","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ced.13751","article-title":"Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma","volume":"44","author":"Chen","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjd.15348","article-title":"BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management","volume":"177","author":"Wu","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.074_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/exd.12975","article-title":"Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions","volume":"25","author":"Ali","year":"2016","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.074_bib8","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/bjd.13610","article-title":"Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors","volume":"172","author":"Vigarios","year":"2015","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.04.074_bib9","first-page":"XD06","article-title":"Unusual skin carcinomas induced by BRAF inhibitor for metastatic melanoma: a case report","volume":"11","author":"Cavalieri","year":"2017","journal-title":"J Clin Diagn Res"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.074_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaad.2015.01.018","article-title":"Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy","volume":"72","author":"Anforth","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.074_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2340\/00015555-2488","article-title":"Development of cutaneous toxicities during selective anti-BRAF therapies: preventive role of combination with MEK inhibitors","volume":"97","author":"Erfan","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"47","key":"10.1016\/j.jaad.2020.04.074_bib12","doi-asserted-by":"crossref","first-page":"83280","DOI":"10.18632\/oncotarget.21059","article-title":"Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF\/MEK inhibitors in cancer patients: a meta-analysis","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.074_bib14","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/0008-5472.CAN-15-2900-T","article-title":"Secondary tumors arising in patients undergoing BRAF inhibitor therapy exhibit increased BRAF-CRAF heterodimerization","volume":"76","author":"Boussemart","year":"2016","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jaad.2020.04.074_bib15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2014.1116","article-title":"Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations","volume":"150","author":"Schrama","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.04.074_bib16","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3389\/fmicb.2018.01806","article-title":"The role of human papillomaviruses and polyomaviruses in BRAF-inhibitor induced cutaneous squamous cell carcinoma and benign squamoproliferative lesions","volume":"9","author":"Purdie","year":"2018","journal-title":"Front Microbiol"},{"issue":"8","key":"10.1016\/j.jaad.2020.04.074_bib17","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/0008-5472.CAN-13-1065-T","article-title":"Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors","volume":"74","author":"Holderfield","year":"2014","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/jamadermatol.2013.2023","article-title":"Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib","volume":"149","author":"Falchook","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2020.04.074_bib19","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1158\/1078-0432.CCR-14-2667","article-title":"Contribution of beta-HPV infection and UV damage to rapid-onset cutaneous squamous cell carcinoma during BRAF-inhibition therapy","volume":"21","author":"Cohen","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.074_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/dsu.12035","article-title":"A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma","volume":"39","author":"Fathi","year":"2013","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archdermatol.2011.3080","article-title":"Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma","volume":"148","author":"Alloo","year":"2012","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.13415","article-title":"Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil","volume":"172","author":"Sinha","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/jid.2012.268","article-title":"Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma","volume":"133","author":"Viros","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaad.2009.09.048","article-title":"Intralesional chemotherapy for nonmelanoma skin cancer: a practical review","volume":"63","author":"Kirby","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.04.074_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jdcr.2019.08.008","article-title":"Triple therapy with intralesional 5-fluorouracil, chemowraps, and acitretin: a well-tolerated option for treatment of widespread cutaneous squamous cell carcinomas on the legs","volume":"5","author":"Manalo","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ajd.12055","article-title":"5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma","volume":"54","author":"Tallon","year":"2013","journal-title":"Australas J Dermatol"},{"issue":"14","key":"10.1016\/j.jaad.2020.04.074_bib27","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1200\/JCO.2013.50.2880","article-title":"Intralesional methotrexate for treatment of invasive squamous cell carcinomas in a patient taking vemurafenib for treatment of metastatic melanoma","volume":"34","author":"Moye","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.jaad.2020.04.074_bib28","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMc1108651","article-title":"Vemurafenib in melanoma with BRAF V600E mutation","volume":"365","author":"Dalle","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jaad.2020.04.074_bib29","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jaad.2020.04.074_bib30","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jamadermatol.2013.21","article-title":"Tracking of second primary melanomas in vemurafenib-treated patients","volume":"149","author":"Dalle","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.04.074_bib32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/ijd.13445","article-title":"Second primary melanoma on a patient undergoing vemurafenib therapy. A case report","volume":"56","author":"Onnis","year":"2017","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.critrevonc.2011.08.005","article-title":"Early detection, prevention and management of cutaneous adverse events\u00a0due to sorafenib: recommendations from the Sorafenib Working Group","volume":"82","author":"Bracarda","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.jaad.2020.04.074_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/dsu.12184","article-title":"Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma","volume":"39","author":"Breaker","year":"2013","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.074_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2230.2006.02223.x","article-title":"Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor","volume":"31","author":"Lacouture","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-11-1344","article-title":"Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1","volume":"18","author":"Arnault","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","article-title":"Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib","volume":"7","author":"Dubauskas","year":"2009","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2020.04.074_bib39","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/j.1524-4725.2009.01289.x","article-title":"Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors","volume":"35","author":"Smith","year":"2009","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000317081","article-title":"Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?","volume":"221","author":"Degen","year":"2010","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-4632.2010.04822.x","article-title":"Sorafenib-induced premalignant and malignant skin lesions","volume":"50","author":"Williams","year":"2011","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/2229-5178.126049","article-title":"Side effects of Sorafenib and sunitinib: a new concern for dermatologist and oncologist","volume":"5","author":"Gole","year":"2014","journal-title":"Indian Dermatol Online J"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib43","first-page":"308","article-title":"Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib","volume":"10","author":"Lynch","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.074_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jdcr.2018.01.001","article-title":"Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib","volume":"4","author":"Aboul-Fettouh","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.074_bib45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/DSS.0000000000001626","article-title":"Development of aggressive squamous cell carcinoma with perineural invasion during ruxolitinib treatment","volume":"45","author":"Dunaway","year":"2019","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.074_bib46","first-page":"508","article-title":"Aggressive skin cancers occurring in patients treated with the Janus kinase inhibitor ruxolitinib","volume":"16","author":"Blechman","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib47","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/bjd.13922","article-title":"Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with ruxolitinib","volume":"173","author":"Fabiano","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.074_bib48","doi-asserted-by":"crossref","first-page":"e13108","DOI":"10.1111\/dth.13108","article-title":"Efficacy and safety of vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities","volume":"32","author":"Spallone","year":"2019","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.074_bib49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jdv.12526","article-title":"Development of squamous cell carcinoma into basal cell carcinoma under treatment with vismodegib","volume":"29","author":"Saintes","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.074_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamadermatol.2013.1798","article-title":"New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases","volume":"149","author":"Aasi","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib51","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2013.01.023","article-title":"Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib","volume":"69","author":"Iarrobino","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.04.074_bib52","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjd.12840","article-title":"Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma","volume":"171","author":"Orouji","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.074_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.074_bib54","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaad.2018.07.004","article-title":"Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and meta-analysis","volume":"79","author":"Xie","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.04.074_bib55","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","article-title":"Eruptive keratoacanthomas associated with pembrolizumab therapy","volume":"153","author":"Freites-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.074_bib57","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jdcr.2019.03.014","article-title":"Eruptive squamous cell carcinomas in metastatic melanoma: an unintended consequence of immunotherapy","volume":"5","author":"Haraszti","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.04.074_bib58","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fonc.2019.00530","article-title":"Immune-related adverse events: a case-based approach","volume":"9","author":"Connolly","year":"2019","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2020.04.074_bib59","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/1346-8138.15101","article-title":"Eruptive squamous cell carcinoma in a patient treated with concomitant pembrolizumab and imiquimod","volume":"46","author":"Kanekura","year":"2019","journal-title":"J Dermatol"},{"issue":"36","key":"10.1016\/j.jaad.2020.04.074_bib60","doi-asserted-by":"crossref","first-page":"e12170","DOI":"10.1097\/MD.0000000000012170","article-title":"Secondary basal cell carcinoma of scalp after radiotherapy: a case report","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1667\/RR4284.S1","article-title":"Ionizing radiation exposure and basal cell carcinoma pathogenesis","volume":"185","author":"Li","year":"2016","journal-title":"Radiat Res"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<8::AID-CNCR3>3.0.CO;2-W","article-title":"Sarcoma arising in irradiated bone: report of eleven cases. 1948","volume":"82","author":"Cahan","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib63","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/0019-5154.43222","article-title":"Clinicopathological evaluation of radiation induced basal cell carcinoma","volume":"53","author":"Meibodi","year":"2008","journal-title":"Indian J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib64","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries","volume":"12","author":"Berrington de Gonzalez","year":"2011","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.jaad.2020.04.074_bib65","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jnci\/djq238","article-title":"Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study","volume":"102","author":"Friedman","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.jaad.2020.04.074_bib66","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/jog.14034","article-title":"Radiation-induced cutaneous angiosarcoma of the abdomen in a patient with cervical cancer: a case report","volume":"45","author":"Shin","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/gcc.20827","article-title":"Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions","volume":"50","author":"Guo","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib68","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canrad.2015.01.001","article-title":"Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast?","volume":"19","author":"Lae","year":"2015","journal-title":"Cancer Radiother"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/1097-0142(195401)7:1<149::AID-CNCR2820070116>3.0.CO;2-X","article-title":"Fibromatosis and fibrosarcoma following irradiation therapy","volume":"7","author":"Pettit","year":"1954","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib70","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jama.1968.03140040048015","article-title":"Fibrosarcoma following radiation therapy","volume":"203","author":"Schwartz","year":"1968","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib71","first-page":"421","article-title":"Radiation-induced fibrosarcoma following treatment for breast cancer","volume":"81","author":"Adam","year":"1977","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib72","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ajcp\/53.3.407","article-title":"Fibrosarcoma of the chest wall following resection and irradiation of carcinoma of the breast","volume":"53","author":"Oberman","year":"1970","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jaad.2020.04.074_bib73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/ajcp\/36.5.427","article-title":"Sarcoma-like tumors of\u00a0the\u00a0skin following irradiation","volume":"36","author":"Rachmaninoff","year":"1961","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.jaad.2020.04.074_bib74","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1097-0142(19820301)49:5<878::AID-CNCR2820490510>3.0.CO;2-R","article-title":"Pleomorphic liposarcoma following radiotherapy for breast carcinoma","volume":"49","author":"Arbabi","year":"1982","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2020.04.074_bib75","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/1097-0142(19800315)45:6<1419::AID-CNCR2820450620>3.0.CO;2-M","article-title":"Postirradiation sarcoma (malignant fibrous histiocytoma) following breast carcinoma: an ultrastructural study of a case","volume":"45","author":"Tsuneyoshi","year":"1980","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2020.04.074_bib76","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/1097-0142(197807)42:1<118::AID-CNCR2820420120>3.0.CO;2-2","article-title":"Postirradiation sarcoma (malignant fibrous histiocytoma) of axilla","volume":"42","author":"Hardy","year":"1978","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib77","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ana.410070405","article-title":"Radiation-induced malignant and atypical peripheral nerve sheath tumors","volume":"7","author":"Foley","year":"1980","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.jaad.2020.04.074_bib78","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/1097-0142(19850815)56:4<761::AID-CNCR2820560411>3.0.CO;2-J","article-title":"Cutaneous postirradiation sarcoma. Ultrastructural evidence of pluripotential mesenchymal cell derivation","volume":"56","author":"Seo","year":"1985","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.jaad.2020.04.074_bib79","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/jnci\/88.24.1848","article-title":"for The Skin Cancer Prevention Study Group. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy","volume":"88","author":"Karagas","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2020.04.074_bib80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fonc.2013.00073","article-title":"Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk","volume":"3","author":"Braunstein","year":"2013","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2020.04.074_bib81","first-page":"967","article-title":"Referral practices to dermatologists for the treatment of radiation dermatitis in the USA: a call for a multidisciplinary approach","volume":"28","author":"Nazarian","year":"2020","journal-title":"Support Care Cancer"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220306897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220306897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:55:20Z","timestamp":1759272920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220306897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0190962220306897"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.074","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.04.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}